Literature DB >> 25714403

Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology?

Lei Zheng1, Christopher L Wolfgang.   

Abstract

Pancreatic cancer has a dismal prognosis. A technically perfect surgical operation may still not provide a survival advantage for patients with technically resectable pancreatic cancer. Appropriate selection of patients for surgical resections is an imminent issue. Recent studies have provided an important clue on what serum biomarkers may be used to select out the patients who would unlikely benefit from the surgical resection.

Entities:  

Keywords:  pancreatic cancer; serum biomarker; surgery

Mesh：

Substances：

Year:  2015        PMID： 25714403      PMCID： PMC4622578          DOI： 10.1080/15384047.2014.1002699

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  13 in total

1.  Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases.

Authors:  Chen Liu; Jiang Long; Liang Liu; Jin Xu; Bo Zhang; Xianjun Yu; Quanxing Ni
Journal:  J Surg Res       Date:  2011-10-01       Impact factor: 2.192

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

4.  A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.

Authors:  Liang Liu; Huaxiang Xu; Wenquan Wang; Chuntao Wu; Yong Chen; Jingxuan Yang; Putao Cen; Jin Xu; Chen Liu; Jiang Long; Sushovan Guha; Deliang Fu; Quanxing Ni; Aminah Jatoi; Suresh Chari; Angela L McCleary-Wheeler; Martin E Fernandez-Zapico; Min Li; Xianjun Yu
Journal:  Int J Cancer       Date:  2014-10-18       Impact factor: 7.396

Review 5.  Pancreatic cancer.

Authors:  Audrey Vincent; Joseph Herman; Rich Schulick; Ralph H Hruban; Michael Goggins
Journal:  Lancet       Date:  2011-05-26       Impact factor: 79.321

6.  A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.

Authors:  Michael B Farnell; Randall K Pearson; Michael G Sarr; Eugene P DiMagno; Lawrence J Burgart; Tamela R Dahl; Nathan Foster; Daniel J Sargent
Journal:  Surgery       Date:  2005-10       Impact factor: 3.982

7.  Ligamentum teres hepatis patch enhances the healing of pancreatic fistula after distal pancreatectomy.

Authors:  Chun-Tao Wu; Wen-Yan Xu; Liang Liu; Jiang Long; Jin Xu; Quan-Xing Ni; Chen Liu; Xian-Jun Yu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2013-12

8.  Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Authors:  Hua-Xiang Xu; Tao Chen; Wen-Quan Wang; Chun-Tao Wu; Chen Liu; Jiang Long; Jin Xu; Ying-Jian Zhang; Run-Hao Chen; Liang Liu; Xian-Jun Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-13       Impact factor: 9.236

9.  Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Authors:  Ioannis T Konstantinidis; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers; David P Ryan; Jennifer A Wargo; Keith D Lillemoe; Cristina R Ferrone
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

10.  CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.

Authors:  Guopei Luo; Zhiwen Xiao; Jiang Long; Zuqiang Liu; Liang Liu; Chen Liu; Jin Xu; Quanxing Ni; Xianjun Yu
Journal:  J Gastrointest Surg       Date:  2013-10-22       Impact factor: 3.452
View more
  4 in total

1.  The crown jewelry of the surgeries for pancreatic cancer.

Authors:  Lei Zheng; Taiping Zhang
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

2.  Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.

Authors:  Jian Wang; Shouhui Yang; Peijun He; Aaron J Schetter; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Matthias M Gaida; Nader Hanna; H Richard Alexander; S Perwez Hussain
Journal:  Clin Cancer Res       Date:  2016-07-08       Impact factor: 12.531

3.  Bioinformatics Analysis of a Prognostic miRNA Signature and Potential Key Genes in Pancreatic Cancer.

Authors:  Shuoling Chen; Chang Gao; Tianyang Yu; Yueyang Qu; Gary Guishan Xiao; Zunnan Huang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

4.  A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms.

Authors:  Chungen Lan; Xin Li; Xiuchao Wang; Jihui Hao; He Ren
Journal:  Cancer Biol Med       Date:  2018-02       Impact factor: 4.248
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.